Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 23, 2020

Aphena Pharma Solutions Announces $21-Million Facility Expansion in Tennessee

The renovations are expected to be completed by Feb. 1, 2021 and, upon completion, Aphena will move its corporate headquarters to the new location.

Aphena Pharma Solutions, a biologics contract manufacturing and packaging company, announced on Sept. 23, 2020 that it has acquired a 500,000 ft2-site in Cookeville, TN, to expand its solid dose division.

The $21-million expansion will provide the company with space to install 24 high-speed bottling lines and eight thermoform blister packaging lines, along with 200,000 ft2of warehouse space for a third-party logistics program, a company press release said. The renovations are expected to be completed by Feb. 1, 2021 and, upon completion, Aphena will move its corporate headquarters to the new location.

“This new facility will make Aphena a top contender in the pharmaceutical contract service space, starting with over 12,000 pallets of cold chain storage capacity,” said Eric Allen, Aphena’s executive vice-president of sales, in the press release. “Being able to offer turnkey packaging and distribution services for biologic products, plus expanding the current operations with newly innovated bottling and packaging lines, will continue to attract key pharmaceutical customers to the middle Tennessee area.”

“This expansion is exciting news for Aphena, our customers and our communities,” added Aphena CEO Shawn Reilley, in the press release. “The solid dose division and recent liquids division expansions will establish Aphena’s position as one of the most diversified manufacturing and packaging companies in the pharmaceutical industry. These growth strategies will continue to offer our customers expanded project capabilities at every level, and it will create a very large employment opportunity, both in Cookeville and at our facility in Easton, Maryland.”

Source: Aphena​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.